Poly medicure Limited has announced a scheduled investor meeting with TCG Asset Management, demonstrating the company's commitment to maintaining regular communication with institutional investors and analysts.

Meeting Details

The company has provided specific details regarding the upcoming investor interaction:

Regulatory Compliance

The meeting is being conducted pursuant to Regulation 30 and applicable provisions of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. Company Secretary Avinash Chandra has formally communicated this information to both BSE Limited and National Stock Exchange of India Limited on March 17, 2026.

Important Disclosures

Poly Medicure Limited has made clear commitments regarding the nature of information sharing during the meeting. The company has specifically stated that no unpublished price sensitive information will be shared during the interaction with TCG Asset Management.

The scheduled meeting remains subject to potential changes due to exigencies that may arise from the analysts, investors, or the company itself. Complete details of this investor meeting schedule are also available on the company's official website at www.polymedicure.com .

This investor engagement reflects Poly Medicure's ongoing efforts to maintain transparent communication with its stakeholder community while adhering to regulatory requirements.

Poly medicure Limited has announced a scheduled one-on-one investor meeting with Avendus Spark, demonstrating the company's commitment to maintaining transparent investor relations and regulatory compliance.

Meeting Details

The company has formally notified both BSE and NSE about the upcoming investor engagement scheduled for March 19, 2026. The meeting will be conducted in a virtual format, reflecting modern business practices and accessibility considerations.

Regulatory Compliance

Poly Medicure Limited has issued this intimation pursuant to Regulation 30 and applicable provisions of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The company has emphasized its commitment to regulatory transparency by formally notifying the stock exchanges about this scheduled investor interaction.

The company has specifically stated that no unpublished price sensitive information will be shared during the meeting, ensuring compliance with insider trading regulations and maintaining market integrity.

Schedule Flexibility

The company has noted that the meeting schedule remains subject to potential changes due to exigencies that may arise from the analysts, investors, or the company itself. This flexibility clause demonstrates practical business considerations while maintaining professional commitment to investor engagement.

The meeting information has been made available on the company's official website at www.polymedicure.com , ensuring broader accessibility for stakeholders and maintaining transparency standards.

Corporate Communication

The formal communication to stock exchanges was signed by Avinash Chandra, Company Secretary (M. No. A32270), on March 12, 2026, demonstrating proper corporate governance procedures and timely disclosure practices.